The DISCO-MS trial looked at the question “Can we define a population of patients in whom it’s safe to discontinue their disease modifying therapy (DMT) for MS as they age?” Dr. John Corboy presents the findings in this webinar.
Your opinions help us shape future education events! Take our brief survey at https://www.surveymonkey.com/r/RSGMGPZ
About the Presenter
Dr. John Corboy is the Medical Director of the Rocky Mountain MS Center and Director of the RMMSC at University of Colorado. He is a graduate of University of Pennsylvania and did his neurology residency there, with a fellowship at Johns Hopkins University in Baltimore. He specialized in MS and neurovirology at the University of Minnesota Medical Center before coming to Colorado in 1994. In 1997, he founded the University of Colorado Multiple Sclerosis Center, now transformed into the Rocky Mountain Multiple Sclerosis Center at University of Colorado, a multidisciplinary group offering state-of-the-art care and research to multiple sclerosis patients. Dr. Corboy is the founding editor of Neurology: Clinical Practice, the clinical journal of the American Academy of Neurology.
If you were not able to tune in, please CLICK HERE to view the webinar.